CAR T-cell therapy, autologous stem cell transplant, and novel agents each have a role to play in the second-line management of patients with primary
See more from OncLive.com
CAR T-cell therapy, autologous stem cell transplant, and novel agents each have a role to play in the second-line management of patients with primary refractory diffuse large B-cell lymphoma. @Lymphoma_Doc @MDAndersonNews #lymsm https://t.co/Cx1sRybyIB https://t.co/Cx1sRybyIB - view on twitter